Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518185

— · D

cc0fc9ac-9a3c-561f-acbc-dee13ff5b02f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.520
  • INTERFERON_GAMMA_RESPONSE+0.460
  • IL6_JAK_STAT3_SIGNALING+0.440
  • INTERFERON_ALPHA_RESPONSE+0.390
  • E2F_TARGETS+0.360
  • G2M_CHECKPOINT+0.310
  • MYC_TARGETS_V1+0.290
  • INFLAMMATORY_RESPONSE+0.280
  • UNFOLDED_PROTEIN_RESPONSE+0.240
  • COMPLEMENT+0.230

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
  • ESTROGEN_RESPONSE_EARLY-0.360
  • ESTROGEN_RESPONSE_LATE-0.300
  • MYOGENESIS-0.300
  • TGF_BETA_SIGNALING-0.290
  • APICAL_SURFACE-0.280
  • UV_RESPONSE_DN-0.280
  • ANGIOGENESIS-0.270
  • NOTCH_SIGNALING-0.270
  • CHOLESTEROL_HOMEOSTASIS-0.250

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518291
breast-umap@18
—D0.942
2BSR_11_0107_E3_S77
breast-umap@18
—D0.893
3SRR1313144
breast-umap@18
—D0.879
4TCGA-BH-A209-01A-11R-A157-07
breast-umap@18
—D0.867
5SRR8518156
breast-umap@18
—D0.866
6SRR8518222
breast-umap@18
—D0.858
7SRR8613787
breast-umap@18
—D0.858
8TCGA-E2-A1II-01A-11R-A144-07
breast-umap@18
—E0.854
9MBCProject_1542_T2_RNA
breast-umap@18
—D0.842
10SRR8518190
breast-umap@18
—D0.837

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.520Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.460Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.440Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.390Inavolisib— uncovered
E2F_TARGETS0.360Inavolisib— uncovered
G2M_CHECKPOINT0.310Inavolisib— uncovered
MYC_TARGETS_V10.290Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.280Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.240Idelalisib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.230Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
KRAS_SIGNALING_UP0.160Inavolisib— uncovered
SPERMATOGENESIS0.140Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.140Inavolisib— uncovered
PANCREAS_BETA_CELLS0.100Cobimetinib— uncovered
HEME_METABOLISM0.090Temsirolimus— uncovered
DNA_REPAIR0.080Idelalisib— uncovered
PROTEIN_SECRETION0.070Remibrutinib— uncovered